Abstract Library

#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors

Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Grabowski P

Authors: Grabowski P, Joehrens K, Arsenic R, Kaemmerer D, Hummel M,

Keywords: Immunophenotype, PD-L1, poorly differentiated NECs, immunotherapy,

#964 Ewing Sarcoma a Dangerous Pitfall for Poorly Differentiated Neuroendocrine Carcinoma (PDEC) in Ileum

Introduction: Ewing sarcoma (ES) primary to the ileum (IES) has rarely been documented, and shows close similarities in histology and clinical presentation with PDEC.EWSR1-FEV translocation is exceedingly rare in ES, as FEV expression is restricted to prostate, brain, and serotonin neuroendocrine cells (NE) and related tumors.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Milione M

Authors: Milione M, Gasparini P, Coppa J, Pusceddu S, Pellegrinelli A,

Keywords: ileum, neuroendocrine, Ewing Sarcoma, EWSR1,

#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy

Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Welin S, Sorby H, Sebjornsen S, Knappskog S, Busch C,

Keywords: chemotherapy, neuroendocrine cancer, PDEC, second-line, temozolomide,

#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors

Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Holt N, Villadsen G, Olesen R, Grønbæk H,

Keywords: poorly differentiated neuroendocrine tumors, PDEC, survival,

#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas

Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,

Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,